Vistagen therapeutics.

... VistaGen Therapeutics. 1. How has your career led you to VistaGen, and why did you choose to move into CNS biopharmaceuticals? I am passionate about ...Sponsor: VistaGen Therapeutics, Inc. Information provided by (Responsible Party):. VistaGen Therapeutics, Inc. Study ...Vistagen Pipeline (Vistagen) The company’s lead program, Fasedienol (PH94B), is a neuroactive nasal spray that could potentially be a breakthrough in the management of social anxiety disorder (SAD).The latest price target for . Vistagen Therapeutics (NASDAQ: VTGN) was reported by Jefferies on Thursday, December 7, 2023.The analyst firm set a price target for 15.00 expecting VTGN to rise to ...

The Investor Relations website contains information about Vistagen Therapeutics, Inc's business for stockholders, potential investors, and financial analysts.

PDF Version. SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 08/13/14 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a stem cell company focused on drug rescue, drug discovery and regenerative medicine, announced today that will implement a 1-for-20 reverse split of its common stock effective at the opening of trading on August 14, …

Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are ...About VistaGen VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's three drug candidates has a differentiated …On March 22, 2023, Vistagen Therapeutics, Inc. (the “C om pany ”) announced positive data from its Phase 3 open-label study designed to evaluate the safety and tolerability of multiple, as-needed intranasal administrations of the Company’s fasedienol (PH94B), over time in adults with social anxiety disorder.Shawn Singh has served as our Chief Executive Officer since August 2009; he joined our Board of Directors in 2000. Mr. Singh has nearly 30 years of experience working with private and public biotechnology, medical device, and pharmaceutical companies, a venture capital firm, and a profitable contract research and development organization (CRO ...The two main types of listening are discriminative and comprehensive. On top of the two basic types of listening, there are more specific types: informational, critical, therapeuti...

Nba season pass

VistaGen Therapeutics (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns ...

Get the latest Vistagen Therapeutics Inc (VTGN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing new generation medicines for depression, SAD and other CNS diseases and disorders with high unmet need. For more information, please visit www.vistagen.com and connect with VistaGen on Twitter , LinkedIn and Facebook .Maggie FitzPatrick. Maggie FitzPatrick joined our Board of Directors in July 2021 and has served as Chair since October 2023. Ms. FitzPatrick is a globally recognized corporate affairs executive who has been honored with several prestigious awards, including the Washington Business Journal’s C-Suite Executive of the Year Class (2019), PR Week ...Vistagen is currently preparing for Phase 2A development of AV-101, on its own or with collaborators, as a treatment for one or more neurological disorders involving the NMDAR. Multiple studies have shown AV-101 to be safe and well-tolerated, and a range of preclinical studies indicate potential in multiple indications, including levodopa ...Vistagen boasts several clinical-stage neuroscience assets in its portfolio, spearheaded by its promising depression-focused drugs, itruvone, fasedienol, and …

A free inside look at VistaGen Therapeutics salary trends based on 4 salaries wages for 4 jobs at VistaGen Therapeutics. Salaries posted anonymously by ...Vistagen Pipeline (Vistagen) The company’s lead program, Fasedienol (PH94B), is a neuroactive nasal spray that could potentially be a breakthrough in the management of social anxiety disorder (SAD).May 4, 2021 · VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system.VistaGen Therapeutics (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns ...The technical indicators of Vistagen Therapeutics Inc show mixed signals. The RSI 5 Day, RSI 9 Day, and RSI 14 Day are 59.56, 61.94, and 62.42 respectively, indicating a neutral market trend.Vistagen Pipeline (Vistagen) The company’s lead program, Fasedienol (PH94B), is a neuroactive nasal spray that could potentially be a breakthrough in the management of social anxiety disorder (SAD).

Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently available for the treatment of anxiety, depression and multiple CNS disorders. Vistagen's pipeline includes six clinical-stage product candidates, including fasedienol (PH94B), itruvone (PH10), …Vistagen Therapeutics had a negative return on equity of 72.10% and a negative net margin of 3,073.51%. The firm had revenue of $0.41 million for the quarter, …

PH80 Overview. PH80 is an odorless, tasteless synthetic investigational pherine with a novel, rapid-onset proposed mechanism of action (MOA) with potential to treat multiple women’s health disorders. PH80’s proposed MOA is fundamentally differentiated from the MOA of all currently approved treatments for vasomotor symptoms (hot flashes) due ... 2 days ago · Vistagen Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings. Amount of Analyst Coverage. Vistagen Therapeutics has received no research coverage in the past 90 days. Read more about Vistagen Therapeutics' stock forecast and price ... VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety ...May 4, 2021 · VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Discover real-time Vistagen Therapeutics, Inc. Common Stock (VTGN) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead with Nasdaq.Vistagen Therapeutics, Inc. 343 Allerton Avenue South San Francisco, CA 94080. Tel: (650) 577-3600 Fax: (888) 482-2602. Investor Relations. Mark A. McPartland Senior Vice President, Investor Relations Vistagen Therapeutics, Inc. T: 650-577-3606 Email: [email protected]. Transfer Agent.A high-level overview of Vistagen Therapeutics, Inc. (VTGN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.In health-care professions, “therapeutic use of self” describes the ability of a caregiver to use his or her personality “consciously and in full awareness in an attempt to establi...

Singapore metro map

Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting and with fewer side effects and safety concerns than those …

Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently ...VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) June 30, March 31, 2022 2022 (unaudited)Shawn Singh has served as our Chief Executive Officer since August 2009; he joined our Board of Directors in 2000. Mr. Singh has nearly 30 years of experience working with private and public biotechnology, medical device, and pharmaceutical companies, a venture capital firm, and a profitable contract research and development organization (CRO ...VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing new generation medicines for depression, SAD and other CNS diseases and disorders with high unmet need. For more information, please visit www.vistagen.com and connect with VistaGen on Twitter , LinkedIn and Facebook .About VistaGen VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's three drug candidates has a differentiated potential mechanism of action, …VistaGen’s lead candidate, PH94B, is a nasally administered spray currently in multiple Phase 3 trials in the U.S., with topline results anticipated in 2022. Should ongoing Phase 3 studies be successful, PH94B has the potential to be the first FDA-approved, fast-acting, acute treatment of anxiety for adults with social anxiety disorder.VistaGen Therapeutics’ core goal is to radically improve mental health and well-being worldwide. Beyond our drug development expertise, we aim to improve the mental health care ecosystem with better outcomes for patients, caregivers, advocates and communities.VistaGen’s CNS pipeline includes three CNS drug candidates, PH94B, PH10 and AV-101, with the potential to go beyond the current standard of care for CNS indications with high unmet need. Each of the Company’s drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date, and has ...VistaGen Therapeutics. Phone: (650) 577-3606. Email: [email protected]. Company Profile VistaGen Therapeutics, Inc. Industry: Pharmaceuticals & Biotechnology Website: https://vistagen.com. PALISADE ...May 4, 2021 · VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. The two main types of listening are discriminative and comprehensive. On top of the two basic types of listening, there are more specific types: informational, critical, therapeuti...On April 25, 2024, Vistagen Therapeutics, Inc. (the "Company") issued a press release to announce positive results from a previously unreported randomized, double-blind, placebo-controlled, crossover Phase 2A pilot study of PH15, the Company's investigational pherine nasal spray, for improvement of psychomotor impairment caused by mental fatigue.

Vistagen Therapeutics. VTGN. $4.76. +0.06 (+1.28%) Share Price. as of April 19 4:00:00 PM EST. Vistagen Therapeutics (VTGN) Stock Price Performance. Vistagen Therapeutics (VTGN) Stock Key Data ...A beaten down micro-cap biotech company, Vistagen Therapeutics Inc., notched its best day ever, surging by as many as four digits after its experimental nasal spray for social anxiety disorder hit ...The intraday chart, the last-five real-time quotes and sales data. Real-time stock quotes can be used to help inform investors when researching potential investment opportunities. VistaGen ...SOUTH SAN FRANCISCO, Calif., Feb. 20, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet medical need, today announced positive results from a newly published …Instagram:https://instagram. photo clearer EX-101.INS - XBRL INSTANCE DOCUMENT: Jun 30, 2020: 10-K: Annual report which provides a comprehensive overview of the company for the past year where can i watch angels in the outfield for free 6 VistaGen Therapeutics jobs. Apply to the latest jobs near you. Learn about salary, employee reviews, interviews, benefits, and work-life balance.Vistagen Therapeutics had a negative return on equity of 72.10% and a negative net margin of 3,073.51%. The firm had revenue of $0.41 million for the quarter, compared to analyst estimates of $0.73 million. As a group, research analysts expect that Vistagen Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year. firma pdf Nov 11, 2023 · VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system. chicago to seattle SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage, central nervous system (CNS) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders, announced today a … fll to austin Vistagen Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings. Amount of Analyst Coverage. Vistagen Therapeutics has received no research coverage in the past 90 days. Read more about Vistagen Therapeutics' stock forecast and price ...Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders. Five of Vistagen ... bend to portland Walk-in tubs are becoming increasingly popular among seniors who want to maintain their independence and safety while bathing. Walk-in tubs provide a safe and comfortable bathing e... cafe rio Vistagen is developing an innovative pipeline of neuroscience medications with the potential to establish new standards of care in the treatment of multiple psychiatric and neurological disorders that disrupt the lives of tens of millions of people in the U.S. and around the world. Learn More.About VistaGen Therapeutics VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue and cell therapy. VistaGen's drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube™, with modern medicinal chemistry to … valorant statistics tracker May 4, 2021 · VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. About VistaGen VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's three drug candidates has a differentiated potential mechanism of action, … find someone's location by phone number SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and Shawn Singh has served as our Chief Executive Officer since August 2009; he joined our Board of Directors in 2000. Mr. Singh has nearly 30 years of experience working with private and public biotechnology, medical device, and pharmaceutical companies, a venture capital firm, and a profitable contract research and development organization (CRO ... flights from chicago to morelia May 4, 2021 · VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. About VistaGen. VistaGen Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company developing new generation medicines for depression and other CNS disorders. VistaGen's lead CNS product candidate, AV-101, is an oral NMDA receptor GlyB antagonist in Phase 2 clinical development in the United States, initially as … gtl inmate The patent relates to the synthesis of AV-101 and certain chemical intermediaries, which synthesis yields AV-101 in commercial quantities and has the scalability for commercial manufacture. The new European patent is a counterpart to previously granted U.S. patent 11,427,530 and will be in effect until at least 2039.Feb 15, 2024 · VistaGen Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.22, expectations were $-0.31. VTGN isn't one of the 30 most popular stocks among hedge funds at the end of the third ...